STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Molecular signaling pathways are crucial for biological regulation; aberrant signaling contributes to cancer development.
• Signal transducer and activator of transcription 3 (STAT3) is an oncogene implicated in promoting cancer cell proliferation, invasion, and chemoresistance.
• STAT3's role is influenced by upstream mediators including microRNAs (miRs), long non-coding RNAs (lncRNAs), and other molecular pathways.

Purpose of the Study:

• To review the role and regulation of STAT3 in gastric cancer (GC).
• To explore the function of miRs and lncRNAs as upstream regulators of STAT3 in GC.
• To discuss potential therapeutic strategies targeting STAT3 and its associated pathways in GC.

Main Methods:

• Literature review focusing on STAT3 signaling in gastric cancer.
• Analysis of studies investigating upstream mediators (miRs, lncRNAs, other pathways) of STAT3.
• Examination of the tumor microenvironment's influence on STAT3 in GC.

Main Results:

• STAT3 promotes GC cell proliferation, invasion, and metastasis by targeting oncogenic factors.
• miRs and lncRNAs act as critical upstream regulators, influencing STAT3's oncogenic or tumor-suppressive roles in GC.
• Anti-tumor compounds can suppress the STAT3 pathway, inhibiting GC cell malignancy.
• Components of the tumor microenvironment, like fibroblasts and macrophages, can target STAT3 in GC.

Conclusions:

• STAT3 is a key driver in gastric cancer progression and metastasis.
• Understanding the upstream regulation of STAT3 by miRs, lncRNAs, and the tumor microenvironment is vital for developing targeted therapies.
• Targeting the STAT3 signaling pathway presents a promising therapeutic avenue for gastric cancer treatment.